CTOs on the Move

Health Plus PHSP Inc

www.healthplus-ny.org

 
Health Plus PHSP Inc is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Gallus Biopharmaceuticals

Gallus Biopharmaceuticals is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

St. Mary Medical Center Foundation

St. Mary Medical Center Foundation is a Langhorne, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kindbody

Kindbody is reinventing healthcare for the modern family, starting with fertility, family-building and wellness benefits. Through a national network of locations, Kindbody is bringing together clinical excellence, best-in-class technology, and accessible pricing — connecting the full patient experience in one, intuitive platform.

Defyned Brands

Headquartered in Austin, we started as a single store with a mission to deliver outstanding results for our customers by providing supplements with the best-in-class ingredients and putting the customer`s experience first. Now more than 10 years later, we have evolved into Defyned Brands, a product development, brand marketing, and multi-channel retail company, owning 5 lifestyle supplement brands and over 50 retail stores under the name 5 Star Nutrition. We are passionate about putting our customers first by helping them reach their health and wellness potential.

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.